Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 17/20 | 0.42 |
| ▸ | PDE4A | P27815 | 14/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410391 | 0.96 | PDE4B (0.46) | PDE4BPDE4APDE4CPDE4DF11 | |
| SCHEMBL2403528 | 0.90 | ACHE (0.47) | PDE4BPDE4APDE4CPDE4DACHE | |
| SCHEMBL2404782 | 0.84 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DL3MBTL1 | |
| SCHEMBL2406045 | 0.84 | PDE4B (0.40) | PDE4BACHE | |
| SCHEMBL2404081 | 0.84 | BLM (0.49) | ACHE | |
| SCHEMBL2405230 | 0.83 | MAPK1 (0.51) | PDE4BPDE4APDE4CPDE4DACHE | |
| SCHEMBL2405482 | 0.81 | PDE4B (0.36) | PDE4BACHE | |
| SCHEMBL2403865 | 0.79 | TDP1 (0.42) | L3MBTL1 | |
| SCHEMBL2406319 | 0.78 | MAPT (0.35) | — | |
| SCHEMBL6023450 | 0.77 | AKR1C3 (0.56) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | PDE4B 822/4885PDE4A 932/4885PDE4C 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.